Skip to main content
Premium Trial:

Request an Annual Quote

Sequenta, Illumina Strike IVD Deal for NGS-based Test to Monitor Residual Disease

NEW YORK (GenomeWeb) – Sequenta and Illumina have struck an agreement to commercialize an in vitro diagnostic kit based on Sequenta's minimal residual disease detection and quantification technology.

Sequenta launched a laboratory-developed test dubbed ClonoSight last year. The test uses proprietary technology to target immune cells and measure MRD in leukemia and lymphoma patients.

"Partnering with Illumina to develop an IVD kit will ultimately enable more doctors to use the prognostic power of Sequenta's MRD detection and quantification technology in caring for their patients," Tom Willis, CEO of Sequenta, said in a statement.

Sequenta noted that testing for MRD can help physicians determine if a cancer treatment has been successful and help guide additional treatment decisions.

Illumina's Nicholas Naclerio, senior vice president of corporate and venture development and general manager, said that the partnership with Sequenta is "consistent with our strategy to support third-party IVD products on our sequencing platform."

In addition, Illumina also said that it participated in Sequenta's recent Series D funding round.